Pasireotide vs Tesamorelin
Overview
Pasireotide is primarily a hormonal peptide, while Tesamorelin is used for performance & growth.
This page compares Pasireotide and Tesamorelin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | Tesamorelin | |
|---|---|---|
| Category | Hormonal | Performance & Growth |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 2 mg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | daily |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | Visceral fat reduction, improved body composition, GH release |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Joint pain, peripheral edema |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while Tesamorelin falls under Performance & Growth. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Pasireotide: FDA-approved. Tesamorelin: FDA-approved.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). Tesamorelin is typically dosed at 2 mg (daily).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and Tesamorelin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and Tesamorelin?
- Pasireotide is primarily a hormonal peptide, while Tesamorelin is used for performance & growth. Pasireotide is FDA-approved for one or more indications, whereas Tesamorelin is FDA-approved for one or more indications.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is Tesamorelin used for?
- GHRH for visceral fat.
- Can you take Pasireotide and Tesamorelin together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and Tesamorelin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or Tesamorelin FDA-approved?
- Pasireotide is FDA-approved for one or more indications. Tesamorelin is FDA-approved for one or more indications.
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- Tesamorelin — full monograph: mechanism, research, dosing & references